Merck's Keytruda succeeds in late-stage lung cancer study

Merck's Keytruda succeeds in late-stage lung cancer study


Merck & Co on Wednesday said its cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer. Keytruda is being studied as a as a first-line treatment for metastatic squamous non-small cell lung cancer patients.



from Biotech News